INTRODUCTION {#sec1}
============

Infection with the hepatitis B and C viruses (HBV and HCV) causes significant morbidity and mortality. Even though HBV infection can be prevented through vaccination, the World Health Organization (WHO) has estimated that globally around 240 million people are chronically infected \[[@ref1], [@ref2]\] with between 500 000 and 700 000 deaths each year \[[@ref1], [@ref3]\]. WHO estimates also indicate that 2--3% of the world\'s population are HCV-infected, equating to 120--170 million people \[[@ref4]\]. About 1·0 million people die annually (∼2·7% of all deaths) from causes related to viral hepatitis, most commonly liver disease, including liver cancer \[[@ref5]\]. An estimated 57% of liver cirrhosis cases and 78% of primary liver cancers result from HBV or HCV infection \[[@ref6]\]. Co-infections with HIV are an increasing problem in countries with HIV epidemics in people who inject drugs (PWID), and in those treated with HIV anti-retrovirals, and underlying viral hepatitis is becoming a major cause of death \[[@ref5]\].

Globally there are geographical variations in the extent of both HBV and HCV infection including within Europe \[[@ref4]\]. In the European Union (EU) and European Free Trade Association (EFTA) area, prevalence in the general population varies from 0·4% to 5·2% for anti-HCV and from 0·1% to 5·6% for HBsAg \[[@ref7]\]. Hepatitis prevalence in the rest of the WHO European Region, mainly eastern Europe and central Asia countries, has not been assessed even though this part of the Region has recently experienced an accelerating HIV epidemic and an increase in the population of PWID \[[@ref8]\].

HBV and HCV are bloodborne viruses that are easily transmitted through blood-to-blood contact \[[@ref2], [@ref9]--[@ref11]\]. Parenteral routes, particularly injecting drug use or poor hygiene in clinical settings, are major sources of transmission \[[@ref2], [@ref9]--[@ref12]\]. HBV can also be transmitted sexually, and this route has also been reported for HCV in certain circumstances \[[@ref10], [@ref13]\]. Perinatal transmission of both HBV and HCV can also occur \[[@ref2], [@ref9], [@ref10]\].

The majority of adults infected with HBV spontaneously resolve their infection and develop protective immunity \[[@ref11]\]. Less commonly chronic infection results and, in rare cases, causes potentially fatal acute liver failure \[[@ref11]\]. In contrast to HBV, the majority of HCV-infected adults develop chronic disease \[[@ref14]\]. Those with chronic infections remain infectious to others and are at risk of developing serious liver disease such as cirrhosis or hepatocellular cancer \[[@ref15], [@ref16]\]. The available antiviral treatments for both HBV and HCV infections have increased and become more effective \[[@ref17], [@ref18]\]. Treatment may also have a role in prevention through reducing the pool of infectious people \[[@ref19]\].

As chronic HBV and HCV infections are largely asymptomatic, many patients who might benefit from treatment remain undetected \[[@ref20]\]. Efforts are needed to detect those infected and who would benefit from treatment, so that the costly sequelae of infection can be reduced \[[@ref21], [@ref22]\]. To target case-finding it is necessary to know which population groups are most affected; and information on the likely numbers infected is needed for healthcare planning, for example, to assess the cost of providing treatment. Examination of these at a regional level allows comparison of the burden between countries as well as informing international responses.

The aims of this study were to: (*a*) assess the prevalence of HBV and HCV infection in the WHO European Region countries outside the EU/EFTA through a literature review; (*b*) generate simple estimates of the numbers living with HBV and HCV infection in these countries, and (*c*) to compare this burden with that in the rest of the WHO European Region obtained from published data \[[@ref7]\].

MATERIALS AND METHODS {#sec2}
=====================

Literature review {#sec2-1}
-----------------

Studies that had measured HBV and HCV seroprevalence since 2000 were identified through a literature review. To be included, studies had to: (*a*) have tested a biological sample (self-reports were excluded) to measure prevalence of HBsAg or anti-HCV in a WHO European Region country outside the EU/EFTA area (*n* = 20, [Table 1](#tab01){ref-type="table"}); (*b*) do so in one or more of these adult population groups: general population, blood donors, pregnant women, PWID, men who have sex with men (MSM), and sex workers; and (*c*) have been published from 2000 to 2010 inclusive. Studies not meeting these criteria or reporting sample sizes \<100 were excluded. Table 1.Number and geographical coverage of studies that had measured the prevalence of hepatitis B surface antigen (HBsAg) or antibodies to the hepatitis C virus (anti-HCV) in each population group by country: countries in the WHO European Region outside EU/EFTA(*a*) General population and blood donorsCountryGeneral populationBlood donorsHBsAgAnti-HCVHBsAgAnti-HCVNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesAlbania3National (x2), 1 city/area11 city/area21 city/area, n.s.21 city/area, n.s.Armenia0000Azerbaijan0000Belarus0000Bosnia & Herzegovina001National2National, 1 city/areaCroatia001National1NationalGeorgia011 city/area00Israel001National1NationalKazakhstan11 city/area2National, 1 city/area1National0Kyrgyzstan012 cities/areas00Montenegro001National1NationalRepublic of Moldova0000Russian Federation2?National, 1 city/area2?National, 1 city/area11 city/area11 city/areaSerbia (incl. Kosovo[\*](#tfn1_2){ref-type="table-fn"})11 city/area11 city/area11 city/area11 city/areaTajikistan01Multi-site1National1NationalThe former Yugoslav Republic of Macedonia0011 city/area11 city/areaTurkey9Multi-site (x2), 1 city/area (x7)7Multi-site, 1 city/area (x6)3National, 1 city/area (x2)3National, 1 city/area (x2)Turkmenistan0000Ukraine4Unclear3Unclear3Unclear2UnclearUzbekistan1Multisite1Multisite1Multisite2Multisite*Total21201818*(*b*) People who injecting drugs (PWID)PWIDHBsAgAnti-HCVNo. ofstudiesCoverage of studiesNo. of studiesCoverage of studiesAlbania11 city/area21 city/areaArmenia00Azerbaijan1Multi-site2Multi-site, 2 cities/areasBelarus1Multi-site2Multi-site, 1 city/areaBosnia & Herzegovina2Multi-site2Multi-siteCroatia3National multi-site, 1 city/area3National, multi-site, 1 city/areaGeorgia31 city/area4Multi-site, 1 city/area (x3)Israel1National1NationalKazakhstan12 cities/areas2National, 2 cities/areasKyrgyzstan02Multi-site, 2 cities/areasMontenegro1Unclear21 city/area, unclearRepublic of Moldova1National1NationalRussian Federation22 cities/areas, 1 city/area16Multi-site (x2), 1 city/area (x12), unclear (x2)Serbia (incl. Kosovo[\*](#tfn1_2){ref-type="table-fn"})11 city/area3Multi-site, 1 city/area (x2)Tajikistan02Multi-site, 1 city/areaThe former Yugoslav Republic of Macedonia00Turkey1Multi-site11 city/areaTurkmenistan00Ukraine31 city/area (x1), unclear (x2)61 city/area (x4), unclear (x2)Uzbekistan02National multi-siteTotal2253(*c*) Men who have sex with men (MSM) and sex workersMSMSex workersHBsAgAnti-HCVHBsAgAnti-HCVNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesNo. of studiesCoverage of studiesAlbania11 city/area000Armenia0000Azerbaijan11 city/area11 city/area1Multi-site1Multi-siteBelarus0000Bosnia & Herzegovina1National1National1National1NationalCroatia11 city/area21 city/area, national01NationalGeorgia11 city/area11 city/area00Israel0000Kazakhstan01National01NationalKyrgyzstan01National03National multi-site, 1 city/areaMontenegro0000Republic of Moldova011 city/area011 city/areaRussian Federation012 cities/areas03Multi-site, 1 city/area (x2)Serbia (incl. Kosovo[\*](#tfn1_2){ref-type="table-fn"})11 city/area11 city/area11 city/area11 city/areaTajikistan0001NationalThe former Yugoslav Republic of Macedonia0000Turkey1Multi-site02Multi-site, 1 city/area11 city/areaTurkmenistan0000Ukraine1Unclear1Unclear1Unclear1UnclearUzbekistan0002Multi-site, 1 city/areaTotal811617[^1][^2]

Medline and EMBASE were searched for studies on the prevalence of HBV and HCV (see Supplementary online material for search terms). The grey literature were indentified through searches of documents held by the WHO Regional Office for Europe, the European Monitoring Centre for Drugs and Drug Addition (EMCDDA) website, and the sources identified in a systematic review on HIV in the WHO European Region -- which had systematically collected data on seroprevalence studies (including those with a focus on viral hepatitis) \[[@ref8]\]. Bibliographies were checked for further sources. The titles and abstracts were first reviewed to identify relevant publication (in English or Russian), the full text was then assessed for inclusion and data extracted (including secondary reports). Data relating to screening of first-time blood donors was obtained from the Council of Europe report \[[@ref23]\].

The prevalences in pregnant women were combined with the general population data. The nature of this population, women of child-bearing age, could mean that the prevalence might not reflect that overall in the general population, particularly if prevalence differs by gender or age, or if fertility rates are higher in migrant groups with higher prevalences; however, we have assumed that such differences are likely to be small overall. Prevalence in first-time blood donors was not combined with the general population data, as blood donors are a highly select group. In most countries those who may have been at risk of infection with bloodborne viruses are excluded from giving blood, thus blood donors are usually likely to be at lower risk overall than the general population.

A 'selected prevalence' estimate in the general population was obtained for each country using the algorithm in [Table 2](#tab02){ref-type="table"}. This was applied to other groups if sufficient studies were identified. Table 2.Algorithm used to select a national prevalencePrevalences were selected using the following hierarchy:(1) National studies.(2) Studies with multiple sites across the country.(3) Regional/city levels studies.If more there was than one study (for example several multi-site studies) then the weight mean was used (or mean if this could not be calculated) to obtain the *selected prevalence.*

Simple estimates of number infected {#sec2-2}
-----------------------------------

The total number of adults currently infected with HBV and HCV was estimated by applying the HBsAg and anti-HCV prevalences to the 2008 national adult (aged ⩾15 years) population estimates \[[@ref24]\]. In countries that had a selected prevalence in blood donors only, the prevalence in the general population was simply imputed from the blood-donor data. This was done by using the median ratio of the blood-donor estimates to the general population estimates for those countries with selected estimates for both of these groups. For countries with no general population and no blood-donor estimate the median of the selected general population\'s prevalences was used. Medians were used as the distributions were skewed, with a small number of countries having a much higher prevalence than the rest; the median thus gives a more conservative estimate than would be obtained using the mean. For HCV, 74% of those anti-HCV positive were assumed to have current infection \[[@ref25]\].

To obtain comparable simple estimates of the numbers living with these infections in the EU/EFTA countries the same method was applied to published data (*n* = 30, excluding four with populations \<100 000). Prevalence in first time blood donors was taken from the Council of Europe report \[[@ref23]\], with additional data from an European Centre for Disease Prevention and Control (ECDC) review \[[@ref7]\] (HBsAg prevalence for 27 countries, anti-HCV for 26). General population prevalences were obtained from the ECDC review, this had obtained selected prevalences for the EU/EFTA countries using a similar method (13 countries HBsAg, 12 anti-HCV) \[[@ref7]\].

The numbers of current PWID infected with HBV and HCV were obtained by applying the selected PWID HBsAg and anti-HCV prevalences to published national estimates of the number of current injectors \[[@ref26], [@ref27]\]. Where national estimates of the current injecting population were not available the median of the national prevalences of injecting drug use was used to impute the number of PWID from the adult population data. For countries with no HBsAg or anti-HCV prevalence estimate for PWID the median of the selected national prevalences was used. Medians were again used as the distributions were skewed. As with the general population for HCV, 74% of those anti-HCV positive were assumed to have current infection \[[@ref25]\].

To obtain comparable simple estimates of the number of PWID living with these infections in the EU/EFTA countries prevalence data from studies undertaken since 1999 was downloaded from the EMCDDA website \[[@ref27]\] (all EU states and Norway report HBV and HCV seroprevalences for PWID to EMCDDA) and literature searches for Switzerland and Iceland (not members of EMCDDA). Selected prevalence estimates were then derived using the same algorithm as above. Numbers were then estimated using the same approach, including imputations for missing data, as for the countries outside EU/EFTA.

RESULTS {#sec3}
=======

After accounting for studies reported by more than one publication, a total 86 sources were identified (Supplementary Fig. S1).

Prevalence: general population and blood donors {#sec3-1}
-----------------------------------------------

Twenty-one studies, undertaken in seven countries (35% of total), had measured HBsAg prevalence in a group representing the general population ([Table 1](#tab01){ref-type="table"}): 11 recruited from the general population, five pregnant women, and five other groups (Supplementary Table S1). Half of these studies had recruited from one city/area ([Table 1](#tab01){ref-type="table"}). Thirteen countries (65%) had measured HBsAg prevalence in blood donors (18 studies, 39% had national coverage, [Table 1](#tab01){ref-type="table"}). Together the general population and blood donor studies covered 13 countries. The study HBsAg prevalences ranged from 0·1% (blood donors, Bosnia & Herzegovina) to 13% (general population, Uzbekistan, Supplementary Table S1). The selected country HBsAg prevalence estimates ([Table 3](#tab03){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}) ranged from 1·3% to 13% for the general population (median 3·4%, mean 5·0%) and from 0·1% to 8·4% for blood donors (median 1·1%, mean 2·2%). The selected general population prevalence was higher than the selected blood-donor prevalence in five of the seven countries with both ([Table 3](#tab03){ref-type="table"}), the median of the ratio between these was 1·4 (range 0·57--2·6, mean 1·6). Fig. 1.Prevalence of antibodies to hepatitis C virus (anti-HCV) and hepatitis B surface antigen (HBsAg) in (*a*) the general adult population; (*b*) people who inject drugs (PWID) in the WHO European region, by country. Hatched areas on maps indicate countries outside the WHO European Region. Table 3.Simple estimates of the number of adults with hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) in WHO European RegionCountryPopulation aged ⩾15 yr in 2008Prevalence in first time blood donorsPrevalence in studies representing general populationPrevalence in general population imputed from blood donors[\*](#tfn3_1){ref-type="table-fn"}Prevalence estimate usedEstimated numbers with infection (rounded to nearest 100)aged ⩾15 yrHBsAgAnti-HCVHBsAgAnti-HCVHBsAgAnti-HCVHBsAgAnti-HCVHBsAgAnti-HCVChronic HCV**Those outside EU/EFTA**Albania2 389 0007·0%0·7%9·0%3·0%11%2·5%MeasuredMeasured215 00071 70053 000Armenia2 431 000Azerbaijan6 549 000Belarus8 228 000Bosnia & Herzegovina3 170 0000·1%0·03%0·1%0·1%Imputed from BDImputed from BD470019001400Croatia3 760 0000·2%0·1%0·3%0·2%Imputed from BDImputed from BD10 20076005600Georgia3 575 0006·7%Measured239 500177 200Israel5 077 0000·1%0·1%0·2%0·2%Imputed from BDImputed from BD830010 4007700Kazakhstan11 796 0001·8%3·8%1·0%2·4%MeasuredMeasured448 200118 00087 300Kyrgyzstan3 790 0001·6%Measured60 60044 900Montenegro498 0000·7%0·6%1·0%1·2%Imputed from BDImputed from BD500059004400Republic of Moldova3 016 000Russian Federation120 185 0001·1%2·1%1·5%3·6%1·5%4·3%MeasuredMeasured1 802 8004 326 7003 201 700Serbia8 068 0004·2%0·3%2·4%0·5%5·7%0·6%MeasuredMeasured193 60040 30029 900Tajikistan4 239 0003·0%2·9%0·5%4·1%5·9%Imputed from BDMeasured171 80021 20015 700FYR Macedonia1 674 0001·0%0·2%1·4%0·5%Imputed from BDImputed from BD22 80075005600Turkey53 958 0002·1%0·3%3·4%0·7%2·9%0·7%MeasuredMeasured1 834 600377 700279 500Turkmenistan3 531 000Ukraine39 554 0001·0%1·3%1·3%12%1·3%2·7%MeasuredMeasured514 2004 746 5003 512 400Uzbekistan19 034 0005·2%6·4%13·3%13·1%7·1%13%MeasuredMeasured2 531 5002 493 5001 845 200Countries without HBsAg31 120 0003·4%Estimated from median prevalence1 058 100Anti-HCV15 527 0002·3%Estimated from median prevalence357 100264 300Total (rounded to nearest 1000)8 821 00012 886 00095 360 000**Those in EU/EFTA**Austria7 087 0000·1%0·1%0·3%0·5%Imputed from BDImputed from BD24 30037 90028 000Belgium8 790 0000·1%0·03%0·7%0·6%0·4%0·3%MeasuredMeasured61 50052 70039 000Bulgaria6 606 0001·8%0·4%1·3%7·9%4·5%Imputed from BDMeasured520 80085 90063 500Cyprus707 0000·1%0·02%0·9%0·4%0·2%MeasuredImputed from BD640014001 000Czech Republic8 875 0000·04%0·13%0·6%0·2%1·3%MeasuredImputed from BD53 300118 00087 300Denmark4 476 0000·03%0·03%0·1%0·3%Imputed from BDImputed from BD610012 4009200Estonia1 140 0000·3%0·7%1·2%7·0%Imputed from BDImputed from BD13 60079 60058 900Finland4 403 0000·03%0·04%0·2%0·1%0·4%MeasuredImputed from BD880017 90013 200France50 870 0000·03%0·02%1·3%0·1%0·2%Imputed from BDMeasured61 400661 300489 400Germany70 748 0000·1%0·1%0·6%0·4%0·6%0·8%MeasuredMeasured424 500283 000209 400Greece9 578 0002·0%0·3%2·1%1·0%8·4%3·3%MeasuredMeasured201 10095 80070 900Hungary8 511 0000·0%0·3%0·0%3·1%Imputed from BDImputed from BD2600267 400197 900Iceland249 000Ireland3 506 0000·01%0·01%0·1%0·1%0·1%MeasuredImputed from BD350031002300Italy51 260 0000·4%1·4%5·2%1·7%MeasuredMeasured717 6002 665 5001 972 500Latvia1 943 000Lithuania2 823 0000·6%1·0%2·6%10·3%Imputed from BDImputed from BD73 900289 800214 500Luxembourg395 0000·1%0·1%0·4%0·6%Imputed from BDImputed from BD170025001800Malta342 000Netherlands13 553 0000·1%0·02%0·1%0·4%0·3%0·2%MeasuredMeasured13 60054 20040 100Norway3 862 0000·03%0·03%0·1%0·4%Imputed from BDImputed from BD440013 60010 000Poland32 389 0000·5%0·2%1·9%2·0%1·9%Imputed from BDMeasured659 800615 400455 400Portugal9 076 0000·1%0·2%0·4%1·7%Imputed from BDImputed from BD36 900157 000116 100Romania18 157 0003·7%0·9%5·6%3·5%15·8%9·2%MeasuredMeasured1 016 800635 500470 300Slovakia4 536 0000·1%0·1%0·6%0·6%0·5%MeasuredImputed from BD27 20024 00017 700Slovenia1 733 0000·1%0·03%0·4%0·4%Imputed from BDImputed from BD750061004500Spain37 814 0000·2%0·1%1·0%2·0%0·7%1·4%MeasuredMeasured378 100756 300559 600Sweden7 641 0000·05%0·1%0·2%0·4%0·2%0·6%MeasuredMeasured15 30030 60022 600Switzerland6 335 0000·2%0·1%0·7%0·6%Imputed from BDImputed from BD44 80040 60030 000United Kingdom50 210 0000·04%0·04%0·7%0·2%0·4%Imputed from BDMeasured86 400351 500260 100Countries without HbsAg2 534 0000·6%Estimated from median prevalence15 200Anti-HCV2 534 0001·2%Estimated from median prevalence29 10021 600Total (rounded to nearest 1000)4 487 0007 387 9005 467 000Total Europe 732 137 00013 308 00020 274 00015 003 0001·8%2·8%2·0%[^3][^4]

Ten countries (50%) had measured the anti-HCV prevalence in groups representing the general population (20 studies: nine recruited from the general population, six pregnant women, five other groups), with two-thirds of these studies covering one city/area ([Table 1](#tab01){ref-type="table"}). Twelve countries (60%) had measured anti-HCV prevalence in blood donors (18 studies, 39% recruited from one city/area, [Table 1](#tab01){ref-type="table"}). Together these measures covered 15 countries (75%). The study anti-HCV prevalences ranged from 0·03% (blood donors, Bosnia & Herzegovina) to 13% (general population, Uzbekistan, Supplementary Table S1). The selected country estimates ([Table 3](#tab03){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}) ranged from 0·5% to 13% for the general population (median 2·3%, mean 4·3%) and from 0·03% to 6·4% for blood donors (median 0·46%, mean 1·3%). The selected general population prevalence was higher than the selected blood-donor prevalence in six of the seven countries with measures of both ([Table 3](#tab03){ref-type="table"}), the median of the ratio between these was 2·1 (range 0·17--9·2, mean 3·0).

Prevalence: PWID {#sec3-2}
----------------

Fourteen (70%) countries had measured HBsAg prevalence and 17 (85%) anti-HCV prevalence in PWID ([Table 1](#tab01){ref-type="table"}). In total 54 studies were identified, including 30 that had recruited from community settings; eight from needle and syringe programmes, low-threshold facilities, harm reduction, or outreach services; three from addiction treatment settings; four through other service types; and five through mixed settings (setting was unclear in four, see Supplementary Table S2). The mean sample size was 650 (range 60--4860, median 319). Twenty-two studies had measured HBsAg (38% recruited in one city/area, [Table 1](#tab01){ref-type="table"}) and 53 studies anti-HCV prevalence (53% recruited in one city/area, [Table 1](#tab01){ref-type="table"}). The study HBsAg prevalences ranged from 0% to 34%, and the anti-HCV prevalences from 5·3% to 95% (Supplementary Table S2). The selected country prevalence estimates ([Table 4](#tab04){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}) ranged from 0·8% to 31% for HBsAg (median 6·8%, mean 9·2%) and from 5·3% to 73% for anti-HCV (median 46%, mean 46%). Table 4.Estimates of number of current hepatitis B and C infections in the WHO European Region: EU/EFTA and non-EU/EFTA comparisonsAdult population(%)Current HBV(%)Current HCV(%)EU/EFTA[\*](#tfn4_1){ref-type="table-fn"}427 615 000(58)4 487 000(34)5 467 000(36)Non EU/EFTA[†](#tfn4_2){ref-type="table-fn"}304 522 000(42)8 821 000(66)9 536 000(64)WHO European Region732 137 000(100)13 308 000(100)15 003 000(100)[^5][^6][^7][^8]

Prevalence: MSM {#sec3-3}
---------------

Thirteen studies were found that had measured the prevalence of either HBsAg or anti-HCV in MSM (Supplementary Table S3). The samples sizes ranged from 61--741 (mean 235, median 157), and the majority had recruited MSM from community settings (11, 85%). Eight (40%) countries had undertaken a single study that had measured the HBsAg prevalence in MSM (five recruited from one city/area, [Table 1](#tab01){ref-type="table"}). The prevalences ranged from 0% to 18% (Supplementary Table S3) with a median of 6·4% (mean 6·9%). Eleven studies (from 10 countries, 50%) reported anti-HCV prevalence in MSM (five recruited from one city/area, [Table 1](#tab01){ref-type="table"}). The median of study anti-HCV prevalence was 4·2% (mean 7·8%, range 0--16%, Supplementary Table S3).

Prevalence: sex workers {#sec3-4}
-----------------------

Seventeen studies (Supplementary Table S4) had measured the prevalence of either HBsAg or anti-HCV in sex workers: samples sizes ranged from 138--2249 (mean 591, median 315). Almost half of the studies (eight, 47%) recruited sex workers from community settings, with four recruiting through services (23%) and two (12%) from both community settings and services (setting unclear for three, Supplementary Table S4). Six studies, from five countries (25%), reported an HBsAg prevalence in sex workers (two recruited from one city/area, [Table 1](#tab01){ref-type="table"}); prevalence ranged from 2% to 18% (Supplementary Table S4), the median was 2·9% (mean 6·1%). Seventeen studies from 12 countries (60%), reported an anti-HCV prevalence in sex workers (seven recruited from one city/area, [Table 1](#tab01){ref-type="table"}); prevalences ranged from 2·4% to 40% (median 11%, mean 14%).

Imputation of general population prevalence from blood donors {#sec3-5}
-------------------------------------------------------------

General population prevalence estimates were imputed from the blood-donor prevalence using the median ratio of the general population to the blood-donor prevalence derived from those countries with both ([Table 3](#tab03){ref-type="table"}). Applying this ratio to the blood-donor prevalence in those countries from which it was derived, gave a median difference between the countries measured and the imputed general population prevalence of 0·004% for HBsAg (range −3·3% to 6·2%, mean 0·6%) and −0·02% for anti-HCV (range −5·4% to 9·3%, mean 0·7%). This variability indicates that a country prevalence imputed this way should be treated with caution.

Simple estimates of total numbers infected {#sec3-6}
------------------------------------------

The selected and imputed prevalences obtained here were applied to population data to produce simple estimates of the numbers infected. These estimates indicate that of the 304·5 million adults living outside the EU/EFTA area 8·8 million (2·9%) have HBsAg and 9·5 million (3·1%) have HCV RNA ([Table 3](#tab03){ref-type="table"}). Comparable estimates for the EU/EFTA countries obtained by applying the same method to published data \[[@ref7]\] ([Table 3](#tab03){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}; the median ratio between the selected general population and the selected blood-donor prevalence used in the imputations was 4·3 for HBsAg and 11 for anti-HCV). These indicated that of the 427·6 million adults in the EU/EFTA countries 4·5 million (1·0%) have HBsAg and 5·5 million (1·3%) have HCV RNA ([Table 3](#tab03){ref-type="table"}). These levels are respectively around one-third and one half of the levels estimated for the area outside the EU/EFTA. Combining these simple estimates indicates that of the 732·1 million adults in the WHO European Region 13·3 million (1·8%) have HBsAg and 15·0 million (2·0%) have HCV RNA; with two-thirds of those living with each infection outside the EU/EFTA area ([Table 4](#tab04){ref-type="table"}).

Simple estimates of total number of infected PWID {#sec3-7}
-------------------------------------------------

The selected and imputed estimates of prevalence in PWID were used to derive simple estimates of the number of current PWID living with HBV and HCV infection outside the EU/EFTA. Considering the wide range in the estimated prevalences of injecting drug use (0·077--3·6%) and in the prevalences of the two infections in PWID (see above) the imputed data should be viewed with great caution. These estimates indicate that of the estimated 3·2 million current PWID outside the EU/EFTA 0·7 million (21%) have HBsAg and 1·5 milion (47%) have HCV RNA ([Table 5](#tab05){ref-type="table"}). Table 5.Simple estimates of the number of people who inject drugs with hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) in WHO European RegionCountryPopulation aged ⩾15 yr in 2008Estimated number of current PWID[\*](#tfn5_1){ref-type="table-fn"}PrevalenceEstimated numbers with infection (rounded to nearest 100)NumberPrevalenceImputed from median prevalenceHBsAgAnti-HCVHBsAgAnti-HCVChronic HCV**Those outside EU/EFTA**Albania2 389 00010 00015%13%15001300900Armenia2 431 00020000·08%Azerbaijan6 549 000300 0004·58%5·9%54%17 700162 700120 400Belarus8 228 00063080·08%13%39%80025001800Bosnia and Herzegovina3 170 00055000·17%2·7%38%10021001500Croatia3 760 00016 7400·45%0·8%46%10077005700Georgia3 575 000127 8333·58%2·9%67%370085 60063 400Israel5 077 00021 0004·3%62%90013 0009600Kazakhstan11 796 000100 0000·85%7·9%60%790060 00044 400Kyrgyzstan3 790 00025 0000·66%54%13 60010 000Montenegro498 000200038%800600Republic of Moldova3 016 00038100·13%6·8%43%30016001200Russian Federation120 185 0001 825 0001·52%31%73%565 8001 332 300985 900Serbia8 068 00018 0000·22%15%52%260094006900Tajikistan4 239 00017 0000·40%33%55004100FYR Macedonia1 674 00026910·16%Turkey53 958 000226 0002·9%5·3%660012 0008900Turkmenistan3 531 00014 000Ukraine39 554 000375 0000·95%12%71%44 000266 300197 000Uzbekistan19 034 00080 0000·42%36%28 80021 300Median prevalence of injecting drug use0·4%Countries without HBsAg estimated using median prevalence142 6916·8%9700Countries without anti-HCV estimated using median prevalence18 69146%86006400Total (rounded to nearest 1000)662 0002 014 0001 490 000**Those in UE/EFTA**Austria^2^7 087 00017 5000·25%53%93006900Belgium^4^8 790 00025 8000·29%3·7%74%100019 10014 100Bulgaria^5^6 606 00020 2500·31%5·5%58%110011 7008700Cyprus^1^707 0004460·06%3·5%36%20200100Czech Republic^1^8 875 00031 2000·35%12%37002700Denmark^1^4 476 00012 7540·28%53%67005000Estonia^4^1 140 00013 8011·21%90%12 4009200Finland^3^4 403 00015 6500·36%42%66004900France^3^50 870 000122 0000·24%45%54 90040 600Germany^5^70 748 00094 2500·13%2·0%75%190070 70052 300Greece^2^9 578 00081480·09%2·5%50%20041003000Hungary^1^8 511 00039410·05%0·5%23%20900700Iceland249 000600Ireland^5^3 506 00062890·18%0·4%72%3045003400Italy^1^51 260 000326 0000·64%59%193 000142 800Latvia^5^1 943 000550074%41003000Lithuania^4^2 823 00051230·18%5·9%73%30037002800Luxembourg^1^395 00014820·38%3·9%81%1001200900Malta^1^342 00090033%300200Netherlands^4^13 553 00031150·02%3·0%77%10024001800Norway^1^3 862 00010 0320·26%1·2%74%10074005500Poland^4^32 389 00088 0004·6%59%400051 90038 400Portugal^2^9 076 00016 4250·18%5·0%46%80076005600Romania^5^18 157 00049 00010%64%500031 40023 200Slovakia^5^4 536 00018 8410·42%50%94007000Slovenia^1^1 733 00073100·42%3·4%22%20016001200Spain^3^37 814 00083 9720·22%73%61 60045 500Sweden^5^7 641 00029 5130·39%88%26 00019 300Switzerland^1^6 335 00031 6530·50%78%24 70018 300United Kingdom^4^50 210 000142 6500·28%46%65 60048 600Median prevalence of injecting drug use0·3%Countries without HBsAg estimated using median prevalence852 5343·5%29 800Countries without anti-HCV estimated using median prevalence60059%400300Total (rounded to nearest 1000)45 000697 000516 000Total Europe (rounded to nearest 1000)706 0002 711 0002 006 000[^9][^10]

Comparable estimates for current PWID living in EU/EFTA countries were derived from published data \[[@ref27]\] by applying the same method ([Table 5](#tab05){ref-type="table"}, [Fig. 1](#fig01){ref-type="fig"}). These estimates for EU/EFTA should be viewed cautiously, as due to the substantial variability in the prevalences (injecting drug use: 0·06--1·2%, median 0·28%, mean 0·31%; HBsAg: 0·3--10%, median 3·5%, mean 3·7%; anti-HCV: 12--88%, median 59%, mean 58%) the imputed data used here are likely to be subject to much uncertainty. The estimation process indicates that of the estimated 1·2 million current PWID in the EU/EFTA area 45000 (3·7%) have HBsAg and 0·5 million (43%) have HCV RNA ([Table 5](#tab05){ref-type="table"}). The proportion with anti-HCV is comparable with the level outside of the EU/EFTA; however, the proportion with HBsAg is much lower ([Table 4](#tab04){ref-type="table"}). Combining these estimates indicates that in current PWID (estimated 4·5 million) across the WHO European Region 0·7 million (15%) have HBsAg and 2·0 million (44%) have HCV RNA ([Table 5](#tab05){ref-type="table"}).

DISCUSSION {#sec4}
==========

Our simple estimates suggest that almost 1/50 adults in the WHO European Region have HBV infection and a similar proportion chronic HCV. Outside of the EU/EFTA area prevalence was around three times higher for HBsAg and over twice as high for HCV RNA. Prevalence of these infections was highest in PWID (15% and 44%, respectively). Although the estimates here need to be viewed with caution, they do suggest a sizable burden due to these two viral infections in the Region, particularly outside the EU/EFTA area.

First, it is important to consider the limitations of this study. The prevalence data on HBsAg and anti-HCV were obtained from literature searches, while grey literature was included, it is possible studies will still have been missed particularly if they have recently been undertaken, reported in languages other than Russian or English, or unpublished. Second, measures of the prevalence of HBsAg and anti-HCV were not identified in all populations or in all countries. In many countries no national studies had been undertaken, thus local and regional data were assumed to be reflective of the whole country. Small studies (*n* \< 100) and those where population was not specifically or clearly defined were excluded; however, we did not asses the methodological quality of the studies, in part because data available was often limited. The studies used a range of designs and thus the robustness of the resulting data is likely to be variable. Where no measure of prevalence was found, simple imputation approaches were applied. Considering these limitations it is important that the findings are viewed cautiously. Even so, the extensive nature of searches undertaken in this assessment mean that it is likely to provide as robust an estimation as is currently practical at the regional level.

In the WHO European Region outside the EU/EFTA, the measured HBsAg and anti-HCV prevalences were highest in PWID, but infection was also common in the general population (3·8% and 2·3%, respectively), MSM (8·7% and 4·2%, respectively), and in sex workers (3·3% and 11%, respectively). There was substantial variation between countries, while prevalence of these infections in PWID was high in most countries; Uzbekistan had a prevalence of 13% for both infections in the general population. The general population HCV prevalence estimate was also elevated in the Ukraine and Georgia, and in Albania the general population HBsAg prevalence estimate was elevated. While these differences might be related to the methodologies used in the studies, they warrant further investigation.

For the general population, PWID and MSM prevalences were higher than in the EU/EFTA area \[[@ref7]\], although comparable data for EU/EFTA was very limited for MSM. The ECDC review \[[@ref7]\] found only two studies from the EU/EFTA countries that had measured HBsAg in MSM \[4% Sweden 1993--1997, and \<1% UK (Scotland) 1993--2003\] and one study that had measured anti-HCV \[1·3% Amsterdam (The Netherlands) 2003\], indicating a need for further studies of prevalence for MSM and other transmission risk populations. For sex workers data on the prevalence of these infections has not been reviewed for the EU/EFTA area, but considering the elevated prevalence found here this is needed. In the countries outside the EU/EFTA, MSM have a higher prevalence of both HBsAg and anti-HCV than the general population, and sex workers had higher anti-HCV prevalence. The high anti-HCV prevalence in MSM and sex workers possibly reflects an overlap with the PWID population \[[@ref8]\]. The higher prevalences of both infections in MSM is a concern considering the evolving epidemic of HIV in this group in parts of central and eastern Europe \[[@ref28]\].

The ratios between the general population estimates and the blood-donor estimates were higher for the EU/EFTA area compared to outside (almost three times higher for HBsAg and about five times higher for anti-HCV). The reasons for this difference are unclear, but it could for example, be due to more success in excluding those who have been at risk of infection from blood donation in the EU/EFTA countries, or be a reflection of the higher prevalence of these infections in the general population outside the EU/EFTA area. This difference needs further investigation.

The estimates of the numbers infected simply applied prevalence to population data; with the prevalences derived from studies using a range of methodologies and imputed for countries with no data (the majority lacked a general population HBsAg estimate). There is some corroboration for the estimates obtained from comparison with published national estimates for HCV. In Italy a modelling approach estimated 2·1 million people chronically infected with HCV in 2000 and 1·9 million in 2005 \[[@ref29]\] compared to the 2·0 million estimated here. In the UK, modelling approaches suggest that around 200 000 people are living with chronic HCV infection \[[@ref30], [@ref31]\], while the simple UK estimate here (*n* = 260 100) is higher it is within the confidence range.

For the PWID estimates there is some corroboration from the UK, where 66 000 current PWID were estimated as HCV-infected in England and Wales \[[@ref30]\] compared to the simple UK estimate here of 48 600 -- though the study had estimated a larger injecting population than the one used here. The estimates of the number of infected PWID obtained here will be particularly uncertain, as estimates of infection prevalence are being simply applied to estimates of the number of current PWID. Both of these are difficult to measure due to the illicit and marginalized nature of injecting drug use, and are thus are likely to be subject to much uncertainty. The estimated number of PWID should thus be used very cautiously. In the UK almost as many former PWID were estimated to have HCV as current PWID \[[@ref30]\]. The estimates obtained here relate to number of infected current PWID, but there will also be many former PWID that will have been infected. It is thus likely that many of the infections in the region not in current PWID will be in former PWID.

A previous estimate had suggested that 14 million people were living with chronic HBV \[[@ref32]\] in the WHO European Region, although the method used for this estimate is not given, it provides some corroboration for the 13·3 million estimated here. In the 1990s, it was estimated from national prevalence data, that there were 8·9 million people living with HCV \[[@ref4]\] in the WHO European Region (prevalence 1·0%), our estimate suggest that HCV infection might have increased over time to 15 million (prevalence 2·0%). If so, this might reflect transmission in PWID, particularly in the east of the Region, where there has been a recent and accelerating epidemic of HIV in PWID \[[@ref33]\].

Viral hepatitis has been recognized as a global public health problem and a World Health Assembly Resolution \[[@ref34]\] has called on Member States to take action to strengthen preventive and control measures. Our findings indicate a large pool of individuals infected with HBV and HCV in the WHO European Region, and so the potential for further transmission. The WHO\'s recent Framework for Global Action to prevent and control viral hepatitis \[[@ref1]\] describes the work needed. Interventions to prevent transmission \[[@ref2], [@ref9], [@ref35]\], including information on safer sex, condom distribution, needle and syringe programmes, and strict infection control practices in healthcare and other settings, need to be maintained and expanded as appropriate. HBV can be prevented through vaccination, national policies should be reviewed regularly, and in those countries with universal vaccination programmes targeted vaccination of high-risk groups should be considered, as recommended by WHO \[[@ref36]\]. Both HBV and HCV can, to varying degrees, be successfully treated. Easy access to diagnostic testing is an important entry point for accessing both prevention and treatment programmes, and in higher prevalence countries targeted screening programmes should be considered for those at greatest risk. Other measures can also reduce the transmission of viral hepatitis, such as, ensuring a safe blood supply.

This study provides useful data for policy makers on the scale of HBV and HCV infection in the region. Policy makers need consider the extent of these diseases when planning health services in order to ensure that appropriate interventions \[[@ref35]--[@ref37]\] are provided on a sufficient scale to reduce the burden arising from these two preventable infections.

These findings indicate that there may be over 13 million adults living with HBV and 15 million with HCV in the WHO European Region -- indicating a large burden for treatment and care. The prevalence of these infections appears to be higher outside the EU/EFTA, with these countries (mainly in eastern Europe and central Asia) accounting for 66% of those with HBsAg and 64% of those with HCV RNA, yet only 42% of the European Region\'s adult population ([Table 4](#tab04){ref-type="table"}). Efforts to prevent, diagnose and treat these infections need to be maintained and improved. Surveillance of the seroprevalence of these infections and related risk behaviours in the affected populations is needed to monitor trends and allow assessment of the impact of interventions.
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[^1]: EU/EFTA, European Union and European Free Trade Association area; n.s., not stated.; '?', preceding a detail indicates that the information available on this item in the source was limited.

[^2]: According to United Nations Security Council Resolution 1244 (1999).

[^3]: BD, Blood donors; FYR Macedonia, Former Yugoslav Republic of Macedonia; Anti-HCV, antibodies to the hpatitis C virus; EU/EFTA, European Union and European Free Trade Association area.

[^4]: Estimated using median of the national ratios of the general population prevalence to prevalence in blood donors.

[^5]: EU/EFTA, European Union and European Free Trade Association area.

[^6]: Twenty-seven EU Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

[^7]: Four EEA/EFTA countries: Norway, Iceland, Liechtenstein, Switzerland.

[^8]: Albania, Armenia, Azerbaijan, Belarus, Bosnia & Herzegovina, Croatia, Georgia, Israel, Kazakhstan, Kyrgyzstan, Montenegro, Republic of Moldova, Russian Federation, Serbia (incl. Kosovo), Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine.

[^9]: FYR, The Former Yugoslav Republic of Macedonia; Anti-HCV, antibodies to the hepatitis C virus; EU/EFTA, European Union and European Free Trade Association area; EU/EFTA HBsAg and anti-HCV data from EMCDDA website plus a literature search for Switzerland and Iceland (^1^ National study; ^2^ weighted mean of national studies; ^3^ multi-city; ^4^ weighted mean from city/sub-region studies; ^5^ one city/region.)

[^10]: Mathers *et al*. \[[@ref26]\], plus data for Bosnia & Herzegovina, Croatia, Czech Republic, Cyprus, Estonia, Greece, Luxembourg, Macedonia, Portugal, Sweden, and United Kingdom from EMCDDA website; and data for Serbia from the Republic of Serbia UNGASS Country Progress Report on AIDS 2010.
